Sunosi: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio

Axsome Therapeutics Inc (NASDAQ: AXSM) has agreed to acquire Sunosi (solriamfetol) from Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) Jazz will receive from Axsome a total upfront payment of $53 million. Axsome expects to finance the transaction via its existing $300 million term loan facility with Hercules Capital Inc. Sunosi is dual-acting dopamine, ...Full story available on Benzinga.com